Sensus Healthcare (NASDAQ:SRTS – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Sensus Healthcare to post earnings of $0.03 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.18. The firm had revenue of $10.66 million during the quarter, compared to analyst estimates of $4.33 million. Sensus Healthcare had a net margin of 14.70% and a return on equity of 9.76%. During the same quarter last year, the business earned ($0.12) EPS. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Sensus Healthcare Trading Up 3.2 %
Shares of NASDAQ:SRTS opened at $6.20 on Wednesday. Sensus Healthcare has a 12 month low of $1.79 and a 12 month high of $6.97. The company has a market capitalization of $101.62 million, a price-to-earnings ratio of 21.38 and a beta of 1.00. The firm’s 50-day moving average is $5.64 and its 200 day moving average is $4.58.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on SRTS
Insider Transactions at Sensus Healthcare
In related news, Director John Heinrich sold 4,773 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $5.95, for a total value of $28,399.35. Following the completion of the sale, the director now owns 75,167 shares in the company, valued at $447,243.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company’s stock.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Stories
- Five stocks we like better than Sensus Healthcare
- Upcoming IPO Stock Lockup Period, Explained
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Trading Halts Explained
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.